81 results
6-K
EX-99.2
SPRC
SciSparc Ltd
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all … current operating expenses consist of two components – research and development expenses, and general and administrative expenses.
Research
6-K
EX-99.2
SPRC
SciSparc Ltd
9 Oct 20
Interim Consolidated Financial Statements
12:00am
projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion … – Financing Activities.”
Operating Expenses
Our current operating expenses consist of two components – research and development expenses, and general
6-K
EX-99.3
SPRC
SciSparc Ltd
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts … current operating expenses consist of two components – research and development expenses, and general and administrative expenses.
Research
6-K
EX-99.2
SPRC
SciSparc Ltd
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts … operating expenses consist of two components – research and development expenses, and general and administrative expenses, including sales and marketing
6-K
EX-99.2
vxi3y dwnlc
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.1
trk929olmsu9v1o
28 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6:27am
6-K
EX-99.1
bm9vu
24 Oct 18
Report of Foreign Private Issuer
6:45am
6-K
EX-99.1
mzzec38e2wwfq7z7
6 Jun 18
Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
4:55pm
6-K
EX-99.2
ryn0potdud
22 Apr 20
Therapix Biosciences Announces Appointment of New CEO
5:30pm
20-F
bf1tp v967xwiuxf1bwa
1 May 17
Annual report (foreign)
12:00am
6-K
EX-99.1
kujd04tp 7dl7
6 Dec 18
Therapix Biosciences Reports Third
6:18am
F-1
pv8pf
27 Feb 24
Registration statement (foreign)
4:15pm
424B4
fz31z0 vre1g2q7
2 Apr 20
Prospectus supplement with pricing info
5:28pm
6-K
EX-99.1
udsr0kv8eeos04q8a6yw
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
4r0i5b4aimlc6wlar7o
29 Dec 22
Interim Consolidated Financial Statements
4:03pm